参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响。方法选择2016年6月～2018年12月我院收治的84例结直肠癌患者作为研究对象，按照随机数字表法分为观察组和对照组，每组各42例，对照组仅进行常规化疗，观察组在此基础上加服参苓白术散，两组均治疗12周。比较两组治疗前后的免疫功能指标、Karnofsky功能状状态（KPS）积分、治疗过程中的不良反应发生情况以及近期临床疗效。结果两组患者治疗前的免疫功能指标、KPS评分比较，差异无统计学意义（P＞0.05）；两组患者治疗后的CD3+、CD4+、CD4+/CD8+均低于治疗前，CD8+、KPS评分高于治疗前，差异有统计学意义（P＜0.05）；观察组患者治疗后的CD3+、CD4+、CD4+/CD8+均低于对照组，CD8+、KPS评分高于对照组，差异有统计学意义（P＜0.05）；观察组疾病控制率为88.10%，高于对照组的69.05%，而发生血尿、蛋白尿、白细胞下降、血小板下降、恶心呕吐、腹泻及腹痛的发生率均低于对照组，差异有统计学意义（P＜0.05）。结论参苓白术散联合化疗治疗结直肠癌患者效果显著，可有效改善患者的免疫功能，提高生存质量和减轻化疗的不良反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王浩咏
	刘国荣

关键词 ：参苓白术散, 结直肠癌, 化疗, 免疫功能, 生活质量, 化疗不良反应

Abstract：Objective To investigate the effect of Shenling Baizhu Powder combined with chemotherapy on immune function and quality of life of colorectal cancer.Methods A total of 84 patients with colorectal cancer admitted to our hospital from June 2016 to December 2018 were enrolled.The randomized digital table method was used to divided patients into observation group and control group,42 cases in each group.The control group only received conventional chemotherapy.On this basis,Shenling Baizhu Powderwas added in the obeservation group,and both groups were treated for 12 weeks.The immune function indicators before and after treatment,the Karnofsky functional status(KPS)score,the occurrence of adverse reactions during the treatment,and the recent clinical efficacy were compared.Results There were no significant differences in the pre-treatment immune function index and KPS score between the two groups(P＞0.05).The CD3+,CD4+,CD4+/CD8+levels in the two groups after treatmentwere lower than those before treatment,CD8+,KPS scores were higher than those before treatment,and the differences were statistically significant(P＜0.05).The CD3+,CD4+,CD4+/CD8+in the observation group after treatment were lower than those in the control group,and the CD8+and KPSscorewere higher than those in the control group,the differences were statistically significant(P＜0.05).The disease control rate of the observation group was 88.10%,which was higher than 69.05%of the control group,and the proportions of hematuria,proteinuria,leukopenia,thrombocytopenia,nausea and vomiting,diarrhea and abdominal pain were lower than those in the control group,the differences were statistically significant(P＜0.05).Conclusion Shenling Baizhu Powder with chemotherapy for patients with colorectal cancer has significant curative effect,which can effectively improve the immune function of patients,improve the quality of life and reduce the adverse reactions of chemotherapy.

Key words： Shenling Baizhu Powder Colorectal cancer Chemotherapy Immune function Quality of life Adverse reactions of chemotherapy

引用本文:

王浩咏；刘国荣. 参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响[J]. 中国当代医药, 2020, 27(9): 78-80转84.
WANG Hao-yong； LI UGuo-rong. Effect of Shenling Baizhu Powder combined with chemotherapy on immune function and quality of life of colorectal cancer. 中国当代医药, 2020, 27(9): 78-80转84.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I9/78

[1]	王尊，付旷.直肠MR预测直肠癌新辅助放化疗疗效的研究进展[J].疑难病杂志，2019，18（3）：315-318.
[2]	马瑞，徐玲，曲秀娟，等.结直肠癌的中药治疗进展[J].辽宁中医杂志，2017，44（10）：2217-2219.
[3]	张宪祥，卢云.美国临床肿瘤学会年会结直肠癌最新诊治进展[J].中华外科杂志，2017，55（10）：793-794.
[4]	张彤，何文婷，杨宇飞.中医药治疗Ⅳ期结直肠癌中医证候及用药规律文献研究[J].中医杂志，2017，58（11）：966-970.
[5]	中华人民共和国卫生和计划生育委员会医政医管局.结直肠癌诊疗规范（2015年版）[J].中国实用外科杂志，2015，35（11）：1177-1191.
[6]	国家中医药管理局.中医病证诊断疗效标准[S].南京：南京大学出版社，1994：68-72.
[7]	Duffaud F，Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer，2000，87（12）：881-886.
[8]	郭文彬.参苓白术散加减方对结直肠癌患者术后化疗免疫功能影响[J].中医药临床杂志，2019，31（1）：149-151.
[9]	侯风刚，石齐，刘宣，等.辨证、辨病治疗在中药预防结直肠癌术后复发转移中的作用[J].中华中医药杂志，2016，31（6）：2154-2160.
[10]	南宝，李烜.参苓白术散加减组方辅助化疗用于晚期结直肠癌的临床观察[J].中国药房，2016，27（33）：4646-4648.
[11]	李悠然，陈邑岐，王浩，等.中药汤剂联合静脉化疗方案对结直肠癌患者细胞免疫功能影响的Meta分析[J].辽宁中医杂志，2016，43（10）：2035-2041.
[12]	罗爱华，张高锋.参苓白术散在局部晚期宫颈癌根治性放疗联合铂类药物化疗中的临床意义[J].中国现代医学杂志，2016，26（17）：125-129.
[13]	Tian T，Chen C，Yang F，et al.Establishment of apoptotic regulatory network for geneticmarkers of colorectal cancer and optimal selection of traditional Chinesemedicine target[J].Saudi JBiol Sci，2017，24（3）：634-643.
[14]	卢冬雪，刘沈林.中医药防治结直肠癌术后复发转移的概况[J].世界中西医结合杂志，2017，12（11）：1620-1623，1628.
[15]	杨迪，丁洁，胡薛莉.参苓白术散联合化疗干预大肠癌晚期随机平行对照研究[J].实用中医内科杂志，2018，32（1）：25-27.
[17]	何文婷，张彤，杨宇飞，等.中医药治疗结直肠癌临床疗效Meta分析及证型分析[J].中医杂志，2018，59（22）：1929-1936.
[16]	Liu SS，ShiQ，LiHJ，etal.Right-and left-sided colorectalcancers respond differently to traditional Chinesemedicine[J].World JGastroenterol，2017，23（42）：7618-7625.